In Vivo is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
Horizon Therapeutics raises $600mm through senior note sale
08 Aug 2019
Horizon Therapeutics PLC (formerly Horizon Pharma PLC; rare and rheumatic diseases) completed a private placement, issuing Citigroup Global Markets and other institutional buyers $600mm aggregate principal amount of 5.5% senior notes due 2027. The company will use the proceeds, as well as about $65mm of its cash on hand, to redeem or prepay $625mm of its outstanding debt (including associated premiums, fees, and accrued interest) from existing term loans and credit facilities.
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?